Trial · NCT03716115
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite measure of concentration of three faecal inflammatory markers | 14-18 days | Composite measure of concentration of three faecal inflammatory markers (myeloperoxidase, neopterin, alpha1-antitrypsin) measured by ELISA |
| Secondary | Lactulose:rhamnose ratio | 14-18 days | Lactulose:rhamnose ratio of concentration in urine samples collected over 2 hours following oral administration of test dose |
| Secondary | Plasma lipopolysaccharide (LPS) | 14-18 days | Plasma LPS concentration measured by limulus amoebacyte lysate assay |
| Secondary | Plasma biomarker lipopolysaccharide binding protein (LBP) | 14-18 days | Plasma LBP concentration measured by ELISA |
| Secondary | Plasma fatty acid binding protein (FABP) | 14-18 days | Plasma FABP concentration measured by ELISA |
| Secondary | Plasma soluble CD14 | 14-18 days | Plasma concentration of soluble CD14 measured by ELISA |
| Secondary | Plasma CD163 | 14-18 days | Plasma concentration of CD163 measured by ELISA |
| Secondary | Plasma CRP | 14-18 days | Plasma concentration of C-reactive protein measured by ELISA |
| Secondary | Plasma albumin | 14-18 days | Plasma concentration of albumin measured by ELISA |
| Secondary | Mortality | 14 days and 28 days | Number of deaths in each treatment allocation group |
| Secondary | Adverse events | 14 days and 28 days | Number of adverse events in each treatment allocation group |
| Secondary | Change in weight and length | 14 days and 28 days | Change in weight and length measured by experienced nurses and expressed as change in weight-for-length z score compared to WHO standard |
| Secondary | Days with diarrhoea | 14-18 days | Number of days during which diarrhoea was experienced assessed by experienced nurses |
| Secondary | Days with fever | 14-18 days | xv. Days with fever (two or more recordings of core temperature of 37.8oC or higher in any 24 h period) |
| Secondary | Villus height: crypt depth ratio | 14-18 days | Change in villus height and crypt depth measured in endoscopic biopsies (Lusaka only) |
| Secondary | Epithelial leakiness | 14-18 days | Leakage of fluorescein into gut lumen assessed by Watson score during confocal laser endomicroscopy (Lusaka only) |
| Secondary | Tertiary Objectives-Tertiary Endpoints- Exploratory work on glyscosylation | 14-18 days | Glycosylation in saliva and biopsies |
| Other | Metabolomics | 14-18 days | Untargeted metabolomic profile by mass spectroscopy, and specific measurement of citrulline, tryptophan and kynurenine |
| Other | Transcriptomic analysis | 14-18 days | Untargeted analysis of mRNA sequencing data from intestinal biopsies |
| Other | Confocal laser endomicroscopy | 14-18 days | Mucosal leakiness measured by observation of plumes and luminal fluorescein during confocal laser endomicroscopy |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03716115/registered